following vaccination , 60 % and 21 % of cold-recombinant bivalent a vaccine recipients and 73 % and 83 % of trivalent inactivated vaccine recipients demonstrated fourfold or greater response in hemagglutination-inhibition antibody titer to a/h1n1 and a/h3n2 , respectively .
C0042210
vaccine
C0042212
inactivated vaccine